FNTA: A Potential Drug Target for Neurological Disorders (G2339)

Target Name: FNTA

NCBI ID: G2339

FNTA

FNTA: A Potential Drug Target for Neurological Disorders

Fusiform neurotrophic factor (FNTA) is a protein that is expressed in various tissues of the central nervous system, including the brain. It is a member of the neurotrophic factor family, which includes proteins that are involved in the maintenance of neural tissue health and function. FNTA has been shown to play a role in the development and progression of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and chronic pain. As a result, FNTA has become a focus of interest for researchers as a potential drug target or biomarker.

Disease association

FNTA has been strongly associated with the development and progression of several neurological disorders, including Alzheimer's disease, Parkinson's disease, and chronic pain. Studies have shown that individuals with Alzheimer's disease have lower levels of FNTA compared to healthy individuals, and that treatment with FNTA have been shown to improve cognitive function and reduce the progression of cognitive decline in these individuals. Similarly, individuals with Parkinson's disease have also been shown to have lower levels of FNTA compared to healthy individuals, and that treatment with FNTA has been shown to improve motor function and reduce the progression of motor neuron loss in these individuals.

In addition to its association with neurological disorders, FNTA has also been shown to play a role in pain modulation. Studies have shown that FNTA is involved in the modulation of pain through its ability to interact with GPR91, a protein that is involved in pain modulation. This interaction between FNTA and GPR91 suggests that FNTA may be a potential drug target for the treatment of chronic pain.

FNTA as a drug target

FNTA has been shown to be involved in the development and progression of several neurological disorders, including Alzheimer's disease, Parkinson's disease, and chronic pain. As a result, FNTA has become a focus of interest for researchers as a potential drug target.

One potential mechanism by which FNTA may be involved in the development and progression of these disorders is by modulating the activity of neural stem cells. Studies have shown that FNTA can interact with the protein PDGF-BB, which is involved in the proliferation and survival of neural stem cells. This interaction suggests that FNTA may be involved in the regulation of neural stem cell proliferation and survival, which could be a potential mechanism of its neurotoxicity.

Another potential mechanism by which FNTA may be involved in the development and progression of these disorders is by modulating the activity of glial cells, which are a type of nerve cell that support and protect nerve fibers. Studies have shown that FNTA can interact with the protein GLT-1, which is involved in the survival and function of glial cells. This interaction suggests that FNTA may be involved in the regulation of glial cell function, which could be a potential mechanism of its neurotoxicity.

FNTA as a biomarker

FNTA has also been shown to be involved in the regulation of neural circuitry, which is the complex network of neurons and their connections that allows for communication and behavior. This suggests that FNTA may be involved in the development and progression of disorders that affect neural circuitry, such as Alzheimer's disease and Parkinson's disease.

In addition to its association with neural circuitry, FNTA has also been shown to be involved in the regulation of neurotransmitter release, which is the process by which neurons communicate with other neurons and with the brain. Studies have shown that FNTA can interact with the protein neurotrophin (NT), which is involved in neurotransmitter release. This interaction suggests that FNTA may be involved in the regulation of neurotransmitter release, which could be a potential mechanism of its neurotoxicity.

Conclusion

Fusiform neurotrophic factor (FNTA) is a protein that is expressed in various tissues of the central nervous system and has been associated with the development and progression of several neurological disorders, including Alzheimer's disease, Parkinson's disease, and chronic

Protein Name: Farnesyltransferase, CAAX Box, Alpha

Functions: Essential subunit of both the farnesyltransferase and the geranylgeranyltransferase complex. Contributes to the transfer of a farnesyl or geranylgeranyl moiety from farnesyl or geranylgeranyl diphosphate to a cysteine at the fourth position from the C-terminus of several proteins having the C-terminal sequence Cys-aliphatic-aliphatic-X. May positively regulate neuromuscular junction development downstream of MUSK via its function in RAC1 prenylation and activation

The "FNTA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FNTA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets